Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth

Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth

The naturally occurring oncolytic herpes simplex virus canerpaturev (C-REV), formerly HF10, proved its therapeutic efficacy and safety in multiple clinical trials against melanoma, pancreatic, breast, and head and neck cancers. Meanwhile, patients with colorectal cancer, which has increased in preva...

Full description

Bibliographic Details
Main Authors: Zhiwen Wu, Toru Ichinose, Yoshinori Naoe, Shigeru Matsumura, Itzel Bustos Villalobos, Ibrahim Ragab Eissa, Suguru Yamada, Noriyuki Miyajima, Daishi Morimoto, Nobuaki Mukoyama, Yoko Nishikawa, Yusuke Koide, Yasuhiro Kodera, Maki Tanaka, Hideki Kasuya
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Molecular Therapy: Oncolytics
Online Access:http://www.sciencedirect.com/science/article/pii/S237277051930052X

Internet

http://www.sciencedirect.com/science/article/pii/S237277051930052X

Similar Items